Sarah Witt

737 total citations · 1 hit paper
6 papers, 560 citations indexed

About

Sarah Witt is a scholar working on Rheumatology, Hematology and Neurology. According to data from OpenAlex, Sarah Witt has authored 6 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Rheumatology, 3 papers in Hematology and 2 papers in Neurology. Recurrent topics in Sarah Witt's work include Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Sarah Witt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Sarah Witt collaborates with scholars based in United States, United Kingdom and Austria. Sarah Witt's co-authors include Terence Rooney, Maxime Dougados, Douglas Schlichting, Paul Emery, Stephanie de Bono, Désirée van der Heijde, Ying‐Chou Chen, Maria Greenwald, Scott D. Beattie and Edit Drescher and has published in prestigious journals such as Brain Research, Annals of the Rheumatic Diseases and Arthritis & Rheumatology.

In The Last Decade

Sarah Witt

6 papers receiving 554 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Sarah Witt

Since Specialization

Citations

This map shows the geographic impact of Sarah Witt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Witt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Witt more than expected).

Fields of papers citing papers by Sarah Witt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Witt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Witt. The network helps show where Sarah Witt may publish in the future.

Co-authorship network of co-authors of Sarah Witt

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Witt. A scholar is included among the top collaborators of Sarah Witt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Witt. Sarah Witt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis 2020 ·Annals of the Rheumatic Diseases ·Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy Fleischmann, John Bradley, Nicole L Byers, David L. Hyslop, Maher Issa, Atsushi Nishikawa, Terence Rooney, Sarah Witt, Christina Dickson, Josef S Smolen, Maxime Dougados	66
2	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis 2019 ·Arthritis & Rheumatology ·Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, Terence Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel Á. González‐Gay, Tsutomu Takeuchi	134
3	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies 2018 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Joel M. Kremer, Paul Emery, Steven H. Zuckerman, Giacomo Ruotolo, Jinglin Zhong, Lei Chen, Sarah Witt, Chadi Saifan, (unknown), James D. Otvos, Margery A. Connelly, William L. Macias, Douglas Schlichting, Terence Rooney, Stephanie de Bono, Iain B. McInnes	47
4	BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) 2017 ·Internal Medicine Journal ·Mark C. Genovese, Désirée van der Heijde, Maxime Dougados, (unknown), Maria Greenwald, Edit Drescher, (unknown), (unknown), Inmaculada de la Torre, Terence Rooney, Sarah Witt, D. Schlichting, Stephanie de Bono, Paul Emery	1
5	Intrastriatally injected botulinum neurotoxin-A differently effects cholinergic and dopaminergic fibers in C57BL/6 mice 2017 ·Brain Research ·Alexander Hawlitschka, Carsten Holzmann, Sarah Witt, (unknown), (unknown), Oliver Schmitt, Andreas Wree, (unknown)	11
6	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study breakdown → 2016 ·Annals of the Rheumatic Diseases ·Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott D. Beattie, Sarah Witt, Inmaculada de la Torre, C. Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery	301

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact